Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 258

Sort by

Sort Order Select

Journal Articles

Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results

Blood (2025) 146 (Supplement 1): 670.

https://doi.org/10.1182/blood-2025-670

Published: 2025

Journal Articles

Novel composite end-points toxicity/progression-free survival (tfPFS) and toxicity-free complete remission (tfCR100) after CAR-T cell therapy for diffuse large B cell lymphoma: Cell therapy consortium analysis.

Veronika Bachanova, Qing Cao, Marie Hu, Supriya Gupta, Miguel-Angel Perales, Olalekan Oluwole, Richard Maziarz, Joseph McGuirk, Andy Chen, Stephen J. Schuster, Gunjan Shah, Anthony Hunter, Jamie Brower, David Porter, Peter Riedell

Blood (2025) 146 (Supplement 1): 400.

https://doi.org/10.1182/blood-2025-400

Published: 2025

Journal Articles

Patient-reported outcomes (PROs) with lisocabtagene maraleucel (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study

Reem Karmali, Franck Morschhauser, Koji Izutsu, Lia Palomba, Kirit Ardeshna, Brian Hill, Manali Kamdar, Stephen J. Schuster, Antonio Pinto, Saurabh Dahiya, Merav Bar, Maria Strocchia, Jinender Kumar, Jeremy Abramson

Blood (2025) 146 (Supplement 1): 709.

https://doi.org/10.1182/blood-2025-709

Published: 2025

Journal Articles

Activity of autologous anti-CD19 chimeric antigen receptor T-cell therapy in CD19-negative large B-cell lymphoma: A cell therapy consortium real world experience

Chen Zhang, Xiaowen Sun, Lei Feng, David Porter, Stephen J. Schuster, Olalekan Oluwole, Veronika Bachanova, Supriya Gupta, Joseph McGuirk, Richard Maziarz, Andy Chen, Sairah Ahmed, Peter Riedell, Anthony Hunter, Paolo Strati

Blood (2025) 146 (Supplement 1): 957.

https://doi.org/10.1182/blood-2025-957

Published: 2025

Journal Articles

Naive CD4+ at apheresis and disease control at infusion are associated with improved efficacy in second-line CAR T-cells

Blood (2025) 146 (Supplement 1): 2755.

https://doi.org/10.1182/blood-2025-2755

Published: 2025

Journal Articles

A newly identified role for IL-5 in regulating CART-associated toxicity and efficacy

Blood (2025) 146 (Supplement 1): 808.

https://doi.org/10.1182/blood-2025-808

Published: 2025

Journal Articles

Precision targeting of pathogenic B cells and autoantibodies in systemic lupus erythematosus using CAR T cells against the IGHV4-34 B cell receptor

Blood (2025) 146 (Supplement 1): 4120.

https://doi.org/10.1182/blood-2025-4120

Published: 2025

Journal Articles

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Blood (2025) 145 (7): 708–719.

https://doi.org/10.1182/blood.2024025454

Published: 2025

Includes: Supplemental data

Journal Articles

BTK Inhibition Prevents the Induction of Myeloid-Derived Suppressor Cells in Malignancy and Improves CART Function

Blood (2024) 144 (Supplement 1): 909.

https://doi.org/10.1182/blood-2024-202659

Published: 2024

Journal Articles

Curing CLL: Long-Term Outcomes of Chronic Lymphocytic Leukemia Patients with at Least One Year of Response to CART-19 Therapy

Benjamin F. Frost, Noelle Frey, Elizabeth O. Hexner, Stephen J. Schuster, Sunita D. Nasta, Alison W Loren, Jakub Svoboda, Daniel J. Landsburg, Bruce Levine, Joseph A. Fraietta, J. Joseph Melenhorst, Elizabeth Veloso, Wei-Ting Hwang, Carl H. June, David L. Porter, Saar Gill

Blood (2024) 144 (Supplement 1): 588.

https://doi.org/10.1182/blood-2024-204197

Published: 2024

Journal Articles

Real-World Outcomes of Early Relapsed/Refractory Large B Cell Lymphoma Patients Treated with 2 nd Line CAR T Therapy

Michael Schneider, Elise A. Chong, Stefan K. Barta, Sunita D. Nasta, Jakub Svoboda, Jordan Carter, Michael Roderick Cook, Nasheed Hossain, Stephen J. Schuster, Heather Difilippo, John P Plastaras, Michael Lariviere, Marco Ruella, David L. Porter, Noelle Frey, Daniel J. Landsburg

Blood (2024) 144 (Supplement 1): 5123.

https://doi.org/10.1182/blood-2024-202736

Published: 2024

Journal Articles

Efficacy and Safety of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-Cell Therapies in Patients with Autoimmune Disease and Lymphoma or Myeloma

Blood (2024) 144 (Supplement 1): 7243.

https://doi.org/10.1182/blood-2024-206608

Published: 2024

Journal Articles

Resolution of Ibrutinib-Associated Hypertension with Transition to Alternate Covalent Bruton's Tyrosine Kinase Inhibitor

Emily B. Tomasulo, Dylan Therwhanger, Emeline R. Chong, Mitchell E. Hughes, Michael G. Fradley, Stephen J. Schuster

Blood (2024) 144 (Supplement 1): 6802.

https://doi.org/10.1182/blood-2024-211719

Published: 2024

Journal Articles

Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II

Blood (2024) 144 (Supplement 1): 1645.

https://doi.org/10.1182/blood-2024-194612

Published: 2024

Journal Articles

Outcomes in Primary CNS Lymphoma: A Single Institution Experience from the Abramson Cancer Center at the University of Pennsylvania

Nikita Dave, Veronica Carvajal, Jordan Carter, Donald Edward Tsai, Stephen J. Schuster, James Gerson, Stefan K. Barta, Jakub Svoboda, Elise A. Chong, Daniel J. Landsburg, Sunita D. Nasta

Blood (2024) 144 (Supplement 1): 1699.

https://doi.org/10.1182/blood-2024-207781

Published: 2024

Journal Articles

Title: Development of a Pathologic Prognostic Index (PPI) for Newly Diagnosed Large B Cell Lymphoma Patients Treated with R-CHOP

Vincent Ni, Sunita D. Nasta, Stefan K. Barta, Stephen J. Schuster, Elise A. Chong, Jakub Svoboda, Jennifer JD Morrissette, Ashley Barlev, Adam Bagg, Salvatore F. Priore, Daniel J. Landsburg

Blood (2024) 144 (Supplement 1): 3083.

https://doi.org/10.1182/blood-2024-203448

Published: 2024

Journal Articles

Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study

Blood (2024) 144 (Supplement 1): 4625.

https://doi.org/10.1182/blood-2024-205223

Published: 2024

Journal Articles

Overcoming the Lack of CD2:CD58 Costimulation in Chimeric Antigen Receptor T-Cell Immunotherapies

Alberto Carturan, Mathew G. Angelos, Raymone Pajarillo, Jesse Rodriguez, Jaryse Harris, Yunlin Zhang, Ekta Singh, Andrew Lee, Ositadimma Ugwuanyi, Ruchi P. Patel, Puneeth Guruprasad, Jean Lemoine, Jong Hyun Cho, Patrizia Porazzi, Stephen J. Schuster, Marco Ruella

Blood (2024) 144 (Supplement 1): 504.

https://doi.org/10.1182/blood-2024-206061

Published: 2024

Journal Articles

Comparison of CRS- and Icans-Related Outcomes for Large B Cell Lymphoma Patients Treated with Commercial Axicabtagene Ciloleucel with or without Prophylactic Dexamethasone

Alison Carulli, Hayden Elliott, Brendan Mangan, James Whittenburg, Elise A. Chong, Sunita D. Nasta, Jakub Svoboda, Stefan K. Barta, David L. Porter, Jordan S. Carter, Michael Roderick Cook, Nasheed Hossain, Saar Gill, Alfred L. Garfall, Christopher Catania, Colleen R. Kucharczuk, Stephen J. Schuster, Noelle Frey, Daniel J. Landsburg

Blood (2024) 144 (Supplement 1): 2275.

https://doi.org/10.1182/blood-2024-203726

Published: 2024

Journal Articles

CD5-Deleted Chimeric Antigen Receptor Cells (Senza5™ CART5) to Enhance Immunotherapy Against T-Cell Non-Hodgkin Lymphoma: A First-in-Human Phase I Clinical Trial

Blood (2024) 144 (Supplement 1): 7221.

https://doi.org/10.1182/blood-2024-201063

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results

Novel composite end-points toxicity/progression-free survival (tfPFS) and toxicity-free complete remission (tfCR100) after CAR-T cell therapy for diffuse large B cell lymphoma: Cell therapy consortium analysis.

Patient-reported outcomes (PROs) with lisocabtagene maraleucel (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study

Activity of autologous anti-CD19 chimeric antigen receptor T-cell therapy in CD19-negative large B-cell lymphoma: A cell therapy consortium real world experience

Naive CD4+ at apheresis and disease control at infusion are associated with improved efficacy in second-line CAR T-cells

A newly identified role for IL-5 in regulating CART-associated toxicity and efficacy

Precision targeting of pathogenic B cells and autoantibodies in systemic lupus erythematosus using CAR T cells against the IGHV4-34 B cell receptor

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

BTK Inhibition Prevents the Induction of Myeloid-Derived Suppressor Cells in Malignancy and Improves CART Function

Curing CLL: Long-Term Outcomes of Chronic Lymphocytic Leukemia Patients with at Least One Year of Response to CART-19 Therapy

Real-World Outcomes of Early Relapsed/Refractory Large B Cell Lymphoma Patients Treated with 2 nd Line CAR T Therapy

Efficacy and Safety of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-Cell Therapies in Patients with Autoimmune Disease and Lymphoma or Myeloma

Resolution of Ibrutinib-Associated Hypertension with Transition to Alternate Covalent Bruton's Tyrosine Kinase Inhibitor

Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II

Outcomes in Primary CNS Lymphoma: A Single Institution Experience from the Abramson Cancer Center at the University of Pennsylvania

Title: Development of a Pathologic Prognostic Index (PPI) for Newly Diagnosed Large B Cell Lymphoma Patients Treated with R-CHOP

Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study

Overcoming the Lack of CD2:CD58 Costimulation in Chimeric Antigen Receptor T-Cell Immunotherapies

Comparison of CRS- and Icans-Related Outcomes for Large B Cell Lymphoma Patients Treated with Commercial Axicabtagene Ciloleucel with or without Prophylactic Dexamethasone

CD5-Deleted Chimeric Antigen Receptor Cells (Senza5™ CART5) to Enhance Immunotherapy Against T-Cell Non-Hodgkin Lymphoma: A First-in-Human Phase I Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only